Johnson & Johnson's CARVYKTI Shows 80% Progression-Free Survival in Standard-Risk Myeloma Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 06 2025
0mins
Should l Buy JNJ?
Source: PRnewswire
- Significant Efficacy: In the CARTITUDE-4 study, 80% of standard-risk multiple myeloma patients remained progression-free at 30 months after receiving CARVYKTI®, demonstrating the therapy's durable efficacy and treatment potential.
- Enhanced Immune Fitness: Patients treated earlier exhibited improved immune fitness, with correlational analyses suggesting that enhanced immune cell profiles are associated with longer progression-free survival (PFS), potentially shifting treatment paradigms.
- Robust Clinical Data: Over 9,000 patients globally have been treated with CARVYKTI®, and the accumulated clinical and real-world data provide a solid foundation for expanding its use, likely driving its application in earlier treatment settings.
- Broad Research Implications: The findings from the CARTITUDE-4 study offer new insights into the application of CARVYKTI® in multiple myeloma treatment, potentially enabling earlier interventions that could improve long-term remission rates.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 240.400
Low
190.00
Averages
218.50
High
240.00
Current: 240.400
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson's AKEEGA Approved by European Commission
- Drug Approval: Johnson & Johnson announced that its dual-action drug AKEEGA has been approved by the European Commission for treating adult patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer, marking a significant advancement in cancer treatment.
- Clinical Trial Support: The approval is supported by data from the Phase 3 AMPLITUDE trial, which demonstrated significant benefits in BRCA-mutated patients, further solidifying its application potential in high-risk patient groups.
- Market Outlook: According to GlobalData's Pharma Intelligence Centre, AKEEGA is projected to generate $178 million in revenue by 2031, indicating strong growth potential for Johnson & Johnson in the prostate cancer treatment market.
- Stock Performance: Johnson & Johnson's stock has traded between $141.50 and $251.71 over the past year, with the latest closing price at $240.40, reflecting positive market sentiment following the drug approval.
See More
Subtle Success of a Neglected Dividend ETF
Dividend Stocks and Investment Considerations: Investors are often drawn to dividend stocks based on their high yields, but it's essential to consider other factors such as the company's dividend growth history and potential challenges that may affect payouts.
Diversification through ETFs: Dividend-focused exchange-traded funds (ETFs) can provide a diversified approach to investing in dividend-paying companies, helping to balance risk and enhance stability in an investment portfolio.
Performance of DGRO ETF: The DGRO ETF, which tracks U.S. companies with a history of dividend growth, has shown strong performance, returning about 13% over the past year and offering a yield of nearly 2%.
Investment Recommendations: Analysts suggest considering a range of dividend stocks, including lesser-known firms, to ensure a well-rounded investment strategy, as they may provide stability and growth potential even in fluctuating market conditions.
See More
Strong Dividends and Innovation Drive Healthcare Stocks
- Strong Dividend Record: Johnson & Johnson has raised its dividend for 50 consecutive years and expects to surpass $100 billion in sales this year for the first time, showcasing its stability and appeal to income-seeking investors amid economic fluctuations.
- Innovative Product Pipeline: Johnson & Johnson is awaiting approval for its robotic-assisted surgery system, Ottava, which could serve as a significant growth driver, while the company is also conducting dozens of clinical trials to expand its pharmaceutical portfolio.
- Leader in Animal Health: Zoetis has increased its dividend by 458% over the past decade, and despite facing safety concerns and competitive pressures, the launch of new products like Lenivia and Portela will support its continued growth in the pet healthcare market.
- Pet Ownership Trend Among Youth: Zoetis is capitalizing on the trend of younger generations increasingly choosing to own pets over having children by introducing innovative medications like Apoquel, which is expected to further solidify its market position and drive future revenue growth.
See More
The Investment Advantage of High-Quality Dividend Stocks
- Dividend Return Comparison: A study by Hartford Funds and Ned Davis Research reveals that dividend stocks have achieved an annualized return of 9.2% from 1973 to 2024, significantly outperforming non-dividend payers at 4.31%, highlighting the long-term investment value of dividend stocks.
- Microsoft's Dividend Power: Microsoft is set to pay over $27 billion in dividends over the next year, with a modest yield of 0.9%, yet its rapid growth in cloud computing and AI solutions provides robust cash flow support, ensuring substantial returns for shareholders.
- ExxonMobil's Stability: ExxonMobil's annual dividend payout of $17.18 billion benefits from its integrated operating model, which helps maintain steady cash flow amid oil price fluctuations, especially with current geopolitical tensions driving prices higher, enhancing its outlook.
- Apple's Dividends and Buybacks: Apple pays $15.27 billion in annual dividends and has repurchased $841 billion in stock since fiscal 2013, demonstrating strong cash flow and commitment to shareholder returns, while its pivot to subscription services is expected to further enhance future profitability.
See More
Top Dividend Stocks to Buy: Johnson & Johnson and Zoetis
- Johnson & Johnson's Stability: Johnson & Johnson expects its 2023 sales to exceed $100 billion for the first time, demonstrating strong revenue and earnings growth despite challenges like patent expirations and drug price negotiations, highlighting its resilience and long-term investment value in the healthcare sector.
- Innovation-Driven Growth: The company is awaiting approval for its robotic-assisted surgery system, Ottava, which could be a significant growth driver, while its pharmaceutical pipeline includes dozens of ongoing clinical trials that enhance its competitive position in the market.
- Zoetis' Market Leadership: As a leader in animal health, Zoetis faces challenges from safety concerns, but the approval of new products Lenivia and Portela presents new growth opportunities, especially given their more favorable dosing frequency compared to predecessors.
- Dividend Growth Potential: Zoetis has increased its dividend by an impressive 458% over the past decade, reflecting its strong cash flow and profitability, making it an attractive option for income-seeking investors, particularly as younger generations increasingly choose pet ownership over having children.
See More
Dividend Stocks Outperform Non-Payers Significantly
- Dividend Return Advantage: A study by Hartford Funds and Ned Davis Research reveals that dividend stocks have achieved an annualized return of 9.2% from 1973 to 2024, more than double the 4.31% of non-payers, highlighting their stability and attractiveness for long-term investors.
- Microsoft's Dividend Power: Microsoft pays a quarterly dividend of $0.91, projecting over $27 billion in payouts to shareholders in the coming year; despite a low yield of 0.9%, its rapid growth in cloud computing and AI solutions provides robust cash flow support.
- ExxonMobil's Robust Model: ExxonMobil's quarterly dividend of $1.03 translates to nearly $17.2 billion annually, with its integrated operating model across upstream, midstream, and downstream assets enhancing its ability to withstand crude oil price fluctuations.
- Strong Bank Stock Returns: JPMorgan Chase's quarterly dividend of $1.50 results in annual payouts of $16.2 billion, benefiting from the Federal Reserve's rate hikes, as banks typically outperform during economic expansions, ensuring steady capital returns.
See More
Johnson & Johnson's AKEEGA Approved by European Commission
- Drug Approval: Johnson & Johnson announced that its dual-action drug AKEEGA has been approved by the European Commission for treating adult patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer, marking a significant advancement in cancer treatment.
- Clinical Trial Support: The approval is supported by data from the Phase 3 AMPLITUDE trial, which demonstrated significant benefits in BRCA-mutated patients, further solidifying its application potential in high-risk patient groups.
- Market Outlook: According to GlobalData's Pharma Intelligence Centre, AKEEGA is projected to generate $178 million in revenue by 2031, indicating strong growth potential for Johnson & Johnson in the prostate cancer treatment market.
- Stock Performance: Johnson & Johnson's stock has traded between $141.50 and $251.71 over the past year, with the latest closing price at $240.40, reflecting positive market sentiment following the drug approval.
See More
Subtle Success of a Neglected Dividend ETF
Dividend Stocks and Investment Considerations: Investors are often drawn to dividend stocks based on their high yields, but it's essential to consider other factors such as the company's dividend growth history and potential challenges that may affect payouts.
Diversification through ETFs: Dividend-focused exchange-traded funds (ETFs) can provide a diversified approach to investing in dividend-paying companies, helping to balance risk and enhance stability in an investment portfolio.
Performance of DGRO ETF: The DGRO ETF, which tracks U.S. companies with a history of dividend growth, has shown strong performance, returning about 13% over the past year and offering a yield of nearly 2%.
Investment Recommendations: Analysts suggest considering a range of dividend stocks, including lesser-known firms, to ensure a well-rounded investment strategy, as they may provide stability and growth potential even in fluctuating market conditions.
See More
Strong Dividends and Innovation Drive Healthcare Stocks
- Strong Dividend Record: Johnson & Johnson has raised its dividend for 50 consecutive years and expects to surpass $100 billion in sales this year for the first time, showcasing its stability and appeal to income-seeking investors amid economic fluctuations.
- Innovative Product Pipeline: Johnson & Johnson is awaiting approval for its robotic-assisted surgery system, Ottava, which could serve as a significant growth driver, while the company is also conducting dozens of clinical trials to expand its pharmaceutical portfolio.
- Leader in Animal Health: Zoetis has increased its dividend by 458% over the past decade, and despite facing safety concerns and competitive pressures, the launch of new products like Lenivia and Portela will support its continued growth in the pet healthcare market.
- Pet Ownership Trend Among Youth: Zoetis is capitalizing on the trend of younger generations increasingly choosing to own pets over having children by introducing innovative medications like Apoquel, which is expected to further solidify its market position and drive future revenue growth.
See More
The Investment Advantage of High-Quality Dividend Stocks
- Dividend Return Comparison: A study by Hartford Funds and Ned Davis Research reveals that dividend stocks have achieved an annualized return of 9.2% from 1973 to 2024, significantly outperforming non-dividend payers at 4.31%, highlighting the long-term investment value of dividend stocks.
- Microsoft's Dividend Power: Microsoft is set to pay over $27 billion in dividends over the next year, with a modest yield of 0.9%, yet its rapid growth in cloud computing and AI solutions provides robust cash flow support, ensuring substantial returns for shareholders.
- ExxonMobil's Stability: ExxonMobil's annual dividend payout of $17.18 billion benefits from its integrated operating model, which helps maintain steady cash flow amid oil price fluctuations, especially with current geopolitical tensions driving prices higher, enhancing its outlook.
- Apple's Dividends and Buybacks: Apple pays $15.27 billion in annual dividends and has repurchased $841 billion in stock since fiscal 2013, demonstrating strong cash flow and commitment to shareholder returns, while its pivot to subscription services is expected to further enhance future profitability.
See More
Top Dividend Stocks to Buy: Johnson & Johnson and Zoetis
- Johnson & Johnson's Stability: Johnson & Johnson expects its 2023 sales to exceed $100 billion for the first time, demonstrating strong revenue and earnings growth despite challenges like patent expirations and drug price negotiations, highlighting its resilience and long-term investment value in the healthcare sector.
- Innovation-Driven Growth: The company is awaiting approval for its robotic-assisted surgery system, Ottava, which could be a significant growth driver, while its pharmaceutical pipeline includes dozens of ongoing clinical trials that enhance its competitive position in the market.
- Zoetis' Market Leadership: As a leader in animal health, Zoetis faces challenges from safety concerns, but the approval of new products Lenivia and Portela presents new growth opportunities, especially given their more favorable dosing frequency compared to predecessors.
- Dividend Growth Potential: Zoetis has increased its dividend by an impressive 458% over the past decade, reflecting its strong cash flow and profitability, making it an attractive option for income-seeking investors, particularly as younger generations increasingly choose pet ownership over having children.
See More
Dividend Stocks Outperform Non-Payers Significantly
- Dividend Return Advantage: A study by Hartford Funds and Ned Davis Research reveals that dividend stocks have achieved an annualized return of 9.2% from 1973 to 2024, more than double the 4.31% of non-payers, highlighting their stability and attractiveness for long-term investors.
- Microsoft's Dividend Power: Microsoft pays a quarterly dividend of $0.91, projecting over $27 billion in payouts to shareholders in the coming year; despite a low yield of 0.9%, its rapid growth in cloud computing and AI solutions provides robust cash flow support.
- ExxonMobil's Robust Model: ExxonMobil's quarterly dividend of $1.03 translates to nearly $17.2 billion annually, with its integrated operating model across upstream, midstream, and downstream assets enhancing its ability to withstand crude oil price fluctuations.
- Strong Bank Stock Returns: JPMorgan Chase's quarterly dividend of $1.50 results in annual payouts of $16.2 billion, benefiting from the Federal Reserve's rate hikes, as banks typically outperform during economic expansions, ensuring steady capital returns.
See More
